Strides Arcolab has reported results for the fourth quarter ended December 31, 2012.
The company has reported 52.53% fall in its net profit at Rs 73.93 crore as compared to Rs 155.76 crore for the same quarter in the previous year. However, total income from the operation of the company has increased by 7.85% at Rs 261.31 crore for quarter under review as compared to Rs 242.29 crore for the quarter ended December 31, 2011.
On consolidated basis, The company has reported 10.55% fall in its net profit at Rs 61.19 crore as compared to Rs 68.41 crore for the same quarter in the previous year. Total income from the operation of the company has decreased by 7.05% at Rs 650.63 crore for quarter under review as compared to Rs 699.95 crore for the quarter ended December 31, 2011.
For the year ended December 31, 2012, the company has posted a fall of 52.53% in its net profit at Rs 55.98 crore as compared to Rs 117.92 crore for the same period in the previous year. However, total income from operation has increased by 8.02% at Rs 830.91 crore for year under review as compared to Rs 769.21 crore for the period ended December 31, 2011.
For the year ended December 31, 2012, on consolidated basis, the company has posted growth of over 3-fold in its net profit at Rs 846.23 crore as compared to Rs 224.47 crore for the same period in the previous year. However, total income from operation has decreased by 8.37% at Rs 2365.67 crore for year under review as compared to Rs 2581.71 crore for the period ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: